461 related articles for article (PubMed ID: 23852808)
21. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients.
Lanza G; Gafà R; Santini A; Maestri I; Guerzoni L; Cavazzini L
J Clin Oncol; 2006 May; 24(15):2359-67. PubMed ID: 16710035
[TBL] [Abstract][Full Text] [Related]
23. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
[TBL] [Abstract][Full Text] [Related]
24. Epigenetically regulated gene expression profiles reveal four molecular subtypes with prognostic and therapeutic implications in colorectal cancer.
Wang X; Liu J; Wang D; Feng M; Wu X
Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33300554
[TBL] [Abstract][Full Text] [Related]
25. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
[TBL] [Abstract][Full Text] [Related]
26. Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial-mesenchymal transition.
Gonzalez RS; Huh WJ; Cates JM; Washington K; Beauchamp RD; Coffey RJ; Shi C
Histopathology; 2017 Jan; 70(2):223-231. PubMed ID: 27560620
[TBL] [Abstract][Full Text] [Related]
27. Microsatellite instability testing and its role in the management of colorectal cancer.
Kawakami H; Zaanan A; Sinicrope FA
Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
Bae JM; Cho NY; Kim TY; Kang GH
Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
[TBL] [Abstract][Full Text] [Related]
29. New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer.
Cohen R; Svrcek M; Dreyer C; Cervera P; Duval A; Pocard M; Fléjou JF; de Gramont A; André T
Curr Oncol Rep; 2016 Mar; 18(3):18. PubMed ID: 26861657
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathological classification of colorectal cancer.
Müller MF; Ibrahim AE; Arends MJ
Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors.
Marcus VA; Madlensky L; Gryfe R; Kim H; So K; Millar A; Temple LK; Hsieh E; Hiruki T; Narod S; Bapat BV; Gallinger S; Redston M
Am J Surg Pathol; 1999 Oct; 23(10):1248-55. PubMed ID: 10524526
[TBL] [Abstract][Full Text] [Related]
32. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
Hutchins G; Southward K; Handley K; Magill L; Beaumont C; Stahlschmidt J; Richman S; Chambers P; Seymour M; Kerr D; Gray R; Quirke P
J Clin Oncol; 2011 Apr; 29(10):1261-70. PubMed ID: 21383284
[TBL] [Abstract][Full Text] [Related]
33. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.
Schlicker A; Beran G; Chresta CM; McWalter G; Pritchard A; Weston S; Runswick S; Davenport S; Heathcote K; Castro DA; Orphanides G; French T; Wessels LF
BMC Med Genomics; 2012 Dec; 5():66. PubMed ID: 23272949
[TBL] [Abstract][Full Text] [Related]
34. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
[TBL] [Abstract][Full Text] [Related]
35. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
[TBL] [Abstract][Full Text] [Related]
36. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer.
Ricker CN; Hanna DL; Peng C; Nguyen NT; Stern MC; Schmit SL; Idos GE; Patel R; Tsai S; Ramirez V; Lin S; Shamasunadara V; Barzi A; Lenz HJ; Figueiredo JC
Cancer; 2017 Oct; 123(19):3732-3743. PubMed ID: 28640387
[TBL] [Abstract][Full Text] [Related]
37. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
[TBL] [Abstract][Full Text] [Related]
38. Diagnosis and management of DNA mismatch repair-deficient colorectal cancer.
Stadler ZK
Hematol Oncol Clin North Am; 2015 Feb; 29(1):29-41. PubMed ID: 25475571
[TBL] [Abstract][Full Text] [Related]
39. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
[TBL] [Abstract][Full Text] [Related]
40. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified.
Ward RL; Turner J; Williams R; Pekarsky B; Packham D; Velickovic M; Meagher A; O'Connor T; Hawkins NJ
J Pathol; 2005 Dec; 207(4):377-84. PubMed ID: 16175654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
